HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.